Larvol Delta - Alethio-Therapeuticsannounced-the-unveiling-of-ATX011-a-rstinclass-mutationagnostic-antibody-with-potential-to-disrupt-the-2B-Essential-Thrombocythemia-ET-market

ATX‑011 - Alethio Therapeutics

https://www.globenewswire.com/news-release/2026/04/16/3275062/0/en/Alethio-Therapeutics-Unveils-ATX-011-a-Breakthrough-Mutation-Agnostic-Antibody-for-Treating-Essential-Thrombocythemia-a-c-2B-Market-and-Strengthens-Leadership-to-Accelerate-Path-to.html

Apr 16, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev